Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: A study of 305 cases

Modern Pathology

Volumn 24, Issue 3, 2011, Pages 425-429

  Sangoi, Ankur R ^a,b   Karamchandani, Jason ^a   Lane, Brooke ^a   Higgins, John P ^a   Rouse, Robert V ^a,c   Brooks, James D ^d   McKenney, Jesse K ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EL CAMINO HOSPITAL   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

brachyury; chordoma; germ cell tumor; metastatic; renal cell carcinoma

Indexed keywords

ANTIBODY; BRACHYURY ANTIBODY; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CANCER DIAGNOSIS; CHORDOMA; CHORIOCARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; TERATOMA; TESTIS; TISSUE MICROARRAY; YOLK SAC TUMOR;

CARCINOMA, RENAL CELL; CELL NUCLEUS; CHONDROSARCOMA; CHORDOMA; DIAGNOSIS, DIFFERENTIAL; FETAL PROTEINS; HUMANS; KIDNEY NEOPLASMS; MALE; PAIRED BOX TRANSCRIPTION FACTORS; T-BOX DOMAIN PROTEINS; TESTICULAR NEOPLASMS; TESTIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UROGENITAL NEOPLASMS;

EID: 79952191933     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.196     Document Type: Article

References (22)

1. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
2. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol 2008;21:1461-1469.
3. Rekhi B, Thorat K, Jambhekar NA, et al. Utility of brachyury as a 'new-age' marker in the diagnosis of chordomas. Mod Pathol 2009;22:21A (Abstract 82).
4. Romeo S, Hogendoorn PC. Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol 2006;209:143-146. (Pubitemid 43805408)
5. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordo-ma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 2008;32:572-580. (Pubitemid 351459578)
6. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-165. (Pubitemid 43805410)
7. Jambhekar NA, Rekhi B, Thorat K, et al. Revisiting chordoma with brachyury, a 'new age' marker: analysis of a validation study on 51 cases. Arch Pathol Lab Med 2010;134:1181-1187.
8. O'Donnell P, Tirabosco R, Vujovic S, et al. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiol 2007;36:59-65. (Pubitemid 44843170)
9. Sangoi AR, Dulai MS, Beck AH, et al. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. Am J Surg Pathol 2009;33:669-681.
10. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (Pubitemid 28331029)
11. Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007;13:2471-2478. (Pubitemid 46698599)
12. Nielsen GP, Mangham DC, Grimer RJ, et al. Chordoma periphericum: a case report. Am J Surg Pathol 2001;25:263-267. (Pubitemid 32167510)
13. Suster S, Moran CA. Chordomas of the mediastinum: clinicopathologic, immunohistochemical, and ultra-structural study of six cases presenting as posterior mediastinal masses. Hum Pathol 1995;26: 1354-1362. (Pubitemid 26001598)
14. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008;35:581-592; vi.
15. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205.
16. Hoffmann NE, Gillett MD, Cheville JC, et al. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 2008;179:474-477.
17. Wahner-Roedler DL, Sebo TJ. Renal cell carcinoma: diagnosis based on metastatic manifestations. Mayo Clin Proc 1997;72:935-941. (Pubitemid 27459429)
18. McKenney JK, Fujiwara M, Higgins JP, et al. Comparison of putative renal cell carcinoma markers in primary adrenal cortical lesions and metastatic renal cell carcinoma: a tissue microarray study of 246 cases. Mod Pathol 2009;22:182A (Abstract 822).
19. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol 2009;22: 1218-1227.
20. Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of meta-static yolk sac tumors. Cancer 2009;115:2640-2651.
21. Mei K, Liu A, Allan RW, et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol 2009;22:1628-1636.
22. Wang F, Liu A, Peng Y, et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immuno-histochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol 2009;33:1529-1539.